Search Results 381-390 of 23322 for B cell lymphomas
... B-cell lymphoma 2 (BCL2) inhibitor. MC1733, Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter pylori ...
Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...
Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity Cancer Res.2012;72:(17)4440-8. Horna P, Olteanu H ...
... B-cell lymphomas. Clinically, four weekly doses of rituximab have proven to be well tolerated and effective in previously untreated as well as relapsed ...
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with follicular lymphoma.
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas. Rochester, Minn. This is a Phase 1b ...
Polatuzumab vedotin-piiq injection is used together with other cancer medicines (eg, bendamustine, rituximab) to treat diffuse large B-cell lymphoma (DLBCL) ...
Blood tests can sometimes show whether anaplastic large cell lymphoma cells are present. Blood tests may be used to test for viruses, including HIV, hepatitis B ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.